Logo

Otsuka Pharmaceutical to Acquire Jnana Therapeutics, Expanding its Autoimmune Portfolio and Drug Discovery Technologies

Share this
Jnana Therapeutics

M&A

Otsuka Pharmaceutical to Acquire Jnana Therapeutics, Expanding its Autoimmune Portfolio and Drug Discovery Technologies

Shots:

  • Otsuka has agreed to acquire Jnana, expanding its autoimmune portfolio & drug discovery tech for $800M upfront at closing & $325M development & regulatory milestones. Acquisition will be concluded in Q3’24
  • The acquisition adds Jnana’s RAPID (next-gen. chemoproteomics platform for drug discovery) & JNT-517 (small molecule SLC6A19 inhibitor) to Otsuka’s portfolio. Jnana is also discovering a small molecule in the autoimmune disease area to target IRF3
  • JNT-517 is being assessed under P-I, with parts A & B finding PK of SAD & MAD, part C determining the relative bioavailability of tablet & suspension formulations in healthy subjects and part D finding the effects on urinary Phe & other amino acids in PKU patients. Its registrational study is anticipated in 2025

Ref: Jnana Therapeutics | Image: Jnana Therapeutics

Related Post: Jnana Therapeutics Entered into a Second Collaboration and License Agreement with Roche to Discover Small Molecule Drugs

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions